Legal Representation
Attorney
Gregory J. Chinlund
USPTO Deadlines
Next Deadline
334 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-06-16)
Due Date
June 16, 2026
Grace Period Ends
December 16, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 16, 2025 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
| Mar 7, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Oct 25, 2020 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Oct 3, 2020 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Oct 3, 2020 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Sep 16, 2020 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jun 16, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| May 15, 2020 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Apr 29, 2020 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Apr 29, 2020 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Mar 31, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 31, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 27, 2020 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Mar 11, 2020 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Mar 11, 2020 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Mar 11, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 25, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 13, 2020 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Jan 10, 2020 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Jan 10, 2020 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Jan 10, 2020 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Dec 21, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 20, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 20, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 23, 2019 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jun 26, 2019 | CNRT | O | NON-FINAL ACTION MAILED | Loading... |
| Jun 26, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 4, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 4, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 4, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 30, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 29, 2019 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jan 18, 2019 | CNRT | O | NON-FINAL ACTION MAILED | Loading... |
| Jan 16, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 21, 2018 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Dec 13, 2018 | CREV | I | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | Loading... |
| Nov 30, 2018 | CRCV | M | CORRECTION TRANSACTION RECEIVED FROM IB | Loading... |
| Nov 13, 2018 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Nov 13, 2018 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Oct 27, 2018 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Oct 26, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 23, 2018 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Oct 19, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 19, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 18, 2018 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 001
Substances for use in cell-based reporter gene assays, namely, assays for research purposes; reagents for medical research purposes; reagents for research purposes; reagents for industrial purposes, namely, reagents for scientific and research use; reagents for chemical analyses, namely, chemical reagents for non-medical purposes; cells and reagents for scientific and research use in testing of pharmaceutical products; cell culture media for scientific and research use, namely, cell lines; components for cell-based analyses using optical methods and containing chemical reagents, namely, cells for scientific and research use
Class 005
Reagents for medical use; diagnostic reagents for medical use; biological reagents for medical use
Class 009
Laboratory apparatus in the nature of instruments for use in performing cell-based assays by means of optic detection, namely, optical quantification apparatus; computer software for use in optic based biological analysis; computer software for use in optic based biological analysis such as tools and methods used during drug development, clinical diagnosis, clinical monitoring or assay development
Class 010
Medical diagnostic apparatus for use in testing assays
Class 042
Cell-based assay services, namely, custom design and development of cell-based biochemical assays; cell-based assay services, namely, custom design and development of cell-based biochemical assays for use in drug development, clinical diagnosis, clinical monitoring or assay development; medical research; clinical research in the field of drug development, clinical diagnosis, clinical monitoring or assay development; scientific research; research and development in the field of diagnostic preparations; pharmaceutical drug development services; conducting clinical trials for others; scientific, medical laboratory research and analysis services; scientific and medical laboratory testing services
Class 044
Medical testing services relating to measurement and quantification of drug levels and immunogenicity in patient samples for diagnostic or treatment purposes; medical services, namely, treating persons based on laboratory analysis; providing medical support in the nature of medical monitoring of patients receiving medical treatments; medical diagnostic testing services
Additional Information
Pseudo Mark
I LITE
Classification
International Classes
001
005
009
010
042
044